A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...
2d
The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...
(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...
TARRYTOWN, N.Y. - Regeneron (NASDAQ:REGN ... received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for its drug candidate ...
FL is one of the most common subtypes of B-cell non-Hodgkin lymphoma ... We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center and pioneering ...
Libtayo received positive phase 3 trial results in high-risk adjuvant cutaneous squamous cell carcinoma (CSCC). Regeneron reported ... on our four blockbuster medicines as we progress our ...
Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback